| 12378230 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi +8 more |
2025-08-05 |
|
| 12331041 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, David James Edmonds, Mark E. Flanagan +7 more |
2025-06-17 |
|
| 12319669 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, Matthew S. Dowling, David James Edmonds, Mark E. Flanagan +9 more |
2025-06-03 |
|
| 11858916 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, David James Edmonds, Mark E. Flanagan +7 more |
2024-01-02 |
$249,725,000 |
| 11802121 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, Matthew S. Dowling, David James Edmonds, Mark E. Flanagan +9 more |
2023-10-31 |
$284,263,000 |
| 11512070 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, Matthew S. Dowling, David James Edmonds, Mark E. Flanagan +9 more |
2022-11-29 |
$2,104,375,000 |
| 11203594 |
Anti-proliferative agents for treating PAH |
Samit Kumar Bhattacharya, Douglas C. Behenna, Kimberly O. Cameron, Ping Chen, Kevin Daniel Freeman-Cook +10 more |
2021-12-21 |
$2,121,061,000 |
| 10934279 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi +8 more |
2021-03-02 |
$1,471,575,000 |
| 10851081 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, Matthew S. Dowling, David James Edmonds, Mark E. Flanagan +9 more |
2020-12-01 |
$390,003,000 |
| 10683281 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi +8 more |
2020-06-16 |
$1,092,312,000 |
| 10676465 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi +8 more |
2020-06-09 |
$602,135,000 |
| 10669259 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, Matthew S. Dowling, David James Edmonds, Mark E. Flanagan +9 more |
2020-06-02 |
$395,652,000 |
| 10208019 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, Matthew S. Dowling, David James Edmonds, Mark E. Flanagan +9 more |
2019-02-19 |
$915,842,000 |
